They did not observe significant differences between clinical outcomes according to density in tumor-infiltrating T lymphocytes (TILs) of CD4+/CD8+ lymphocytes, regulatory T-cells (Tregs) (based on FOXP3 expression), peritumoral and stromal myeloperoxidase myeloid cells, and PD-1+ and PD-L1+ immune cells. The gene discussed is CD8A; the disease is neoplasm.